Kidney & Bladder: What's New?
Weekday Course
ORGANIZERS: Nandita
DeSouza, Durgesh Dwivedi
Tuesday, 07 May 2024
Summit 1
15:45 - 17:45
Moderators: Pim
Pullens & Wen-Chau Wu
Skill Level: Intermediate
to Advanced
Session Number: Tu-05
CME Credit
Session Number:
Tu-05
Overview
This course addresses new approaches in imaging renal masses,
renovascular disease, and bladder cancer. It also explores the
advantages and challenges of urinary tract MRI in a pediatric
population.
Target Audience
Clinicians with an interest and practice in urinary imaging, including
those with an interest in pediatric urinary disease. Scientists with an
interest in technical challenges of imaging the kidneys and bladder.
Educational Objectives
As a result of attending this course, participants should be able to:
- Define the role of MRI in staging renal and bladder cancers;
- Explore the role of MRI for active surveillance of renal masses; and
- Describe the usage of MR urography in a pediatric population.
15:45 |
 |
MRI for Active Surveillance of Renal Masses
Kye Jin Park
Keywords: Body: Kidney, Cross-organ: Cancer
Synopsis:
- Introduction: Active
surveillance of renal mass is defined as serial imaging
that monitors serial changes regarding growth and
morphology.
- Patient selection:
According to several published guidelines and white
papers, small renal masses especially < 2 cm with
significant comorbidities and/or limited life expectancy
are eligible for active surveillance.
- Active surveillance
of solid renal masses: The role of MRI will be discussed
with the use of the clear cell likelihood ratio as a
supportive tool.
- Active surveillance
of cystic renal masses: Serial changes in morphology is
important in cystic renal masses.
|
16:15 |
|
Renovascular Disease
Alexandra Ljimani
|
16:45 |
|
MR Urography: Challenges in a Paediatric Population
Cemre Ariyurek
|
17:15 |
|
Bladder Cancer: Staging & Characterization
Nicolas Landini
|